top of page


Shionogi agrees $2bn acquisition of IntraBio to expand rare disease portfolio
Shionogi has agreed to acquire IntraBio for $2 billion, adding the rare neurological disease therapy AQNEURSA and its global commercial rights to the Japanese group's portfolio.

nuaxia
Oct 52 min read


FDA approves Aqneursa as first treatment for ataxia in ataxia-telangiectasia
The FDA has approved Aqneursa as the first treatment specifically indicated for ataxia in adults and children with ataxia-telangiectasia weighing at least 15kg.

nuaxia
Sep 221 min read
bottom of page